Aptose Biosciences 8-K: Press Release Furnished, No New Financial Data

Rhea-AI Filing Summary

Aptose Biosciences Inc. (NASDAQ: APTO) filed a Form 8-K dated June 20, 2025 to disclose an Item 7.01 Regulation FD communication. The filing states that the company issued a press release on the same date, attached as Exhibit 99.1.

The 8-K expressly notes that, under General Instruction B.2, the press release is being “furnished” rather than “filed”, meaning it is not incorporated into Exchange Act reports unless specifically referenced. No financial results, strategic transactions, or operational updates are contained in the 8-K itself, and the exhibit text is not included in the filing excerpt provided.

Insights

Financial Analyst

TL;DR: Routine 8-K furnishes a press release; no financial metrics or material events disclosed.

The company is simply meeting disclosure obligations by furnishing a press release as a Regulation FD exhibit. Because the exhibit content is not provided, investors have no data on revenue, pipeline progress, or liquidity. The absence of any Item 2.02, 5.02, or 8.01 items implies that the release likely contains non-material or previously announced information. Impact to valuation or outlook is minimal until the press release itself is reviewed.

Corporate Governance Expert

TL;DR: Compliance-oriented filing; governance posture unchanged, impact negligible.

This 8-K demonstrates standard compliance with SEC Regulation FD. No board or management changes, litigation issues, or strategic shifts are reported. The signature by CEO Dr. William G. Rice confirms appropriate authorization. Investors should consult Exhibit 99.1 for any substantive content, but the filing itself carries no governance or risk signal.

false 0000882361 0000882361 2025-06-20 2025-06-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 20, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On June 20, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit Number		Description
99.1		Press Release dated June 20, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: June 20, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

Why did Aptose Biosciences (APTO) file a Form 8-K on June 20, 2025?

To furnish a press release under Item 7.01 Regulation FD; no other items were reported.

Does the 8-K include new financial results for APTO?

No. The filing contains no financial statements or earnings data.

Is the attached press release considered "filed" with the SEC?

No. The company specifies the release is furnished under Instruction B.2 and is not incorporated by reference.

Were there any executive or board changes disclosed in this 8-K?

No leadership changes were reported; the document was signed by Chairman & CEO Dr. William G. Rice.